ACRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aclaris Therapeutics Inc (ACRS) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak technical indicators, declining financial performance, and lacks recent positive news or significant trading trends. While analysts have a positive long-term outlook with a $10 price target, the current market conditions and lack of immediate catalysts do not support an entry point for this investor profile.
The MACD is negatively expanding, RSI is neutral at 38.301, and moving averages are converging, indicating no clear upward momentum. The stock is trading below the pivot level of 3.522, with key support at 3.313 and resistance at 3.731. Overall, the technical indicators suggest a weak trend.
Analysts have initiated coverage with a Buy rating and a $10 price target, citing potential upside from Phase 1b data in the second half of 2026.
No recent news or significant trading trends. Financial performance in Q3 2025 shows declining revenue (-24.09% YoY) and gross margin (-42.21% YoY). The stock has a 30% probability of declining further in the short term.
In Q3 2025, revenue dropped by 24.09% YoY to $3.299M, and gross margin decreased by 42.21% YoY to 25.77%. However, net income improved by 92.64% YoY to -$14.614M, and EPS increased by 9.09% YoY to -0.12.
Craig-Hallum initiated coverage with a Buy rating and a $10 price target, citing potential upside from upcoming Phase 1b data and undervaluation of ATI-052.
